Hearing: Repurposing Therapeutic Drugs for COVID-19: Research Challenges and Opportunities [video] [open html - 0B]
This is the June 19, 2020 hearing on "Repurposing Therapeutic Drugs for COVID-19 [coronavirus disease 2019]: Research Challenges and Opportunities," held before the U.S. House Committee on Science, Space, and Technology. From the Opening Statement of Bill Foster: "Today's hearing revolves around one of humanity's most promising tools in its public health response to the current pandemic: repurposing existing therapeutic drugs to treat COVID-19 [coronavirus disease 2019]. The appeal of repurposing existing therapeutics is obvious. These drugs have already been developed; they have already been manufactured, and in many cases can quickly be accessed in large quantities; and for drugs that have already been approved to treat other diseases, a certain amount of safety data is already available to regulators. In the absence of any COVID-19 vaccine or novel treatment, existing therapeutics could potentially offer critical assistance for severely ill patients and bridge the gap until more prevention and treatment options become available. But with great promise comes great temptation. Since existing therapeutics rest at our fingertips and have demonstrated benefits in other circumstances, it can be all too easy in the midst of a pandemic to cut corners and seek shortcuts to longstanding regulatory processes." Statements, letters, and materials submitted for the record include those of the following: Peter Lurie, James Finigan, Rick L. Stevens, and Benjamin Rome. The duration of this video is 1 hour, 36 minutes, and 39 seconds.